ScripAmid the ongoing global financial strains and a high interest rate environment, bioventures in South Korea are increasingly opting to raise funds through rights offerings, despite concerns over share
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Curon Picks Up China-Plus Rights to Rhi